

L8 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2003 ACS

AB Protein isoprenyl transferase inhibitors R3XC6H2R1R2R4 [R1 = H, alkyl, halo, aryl, heterocyclyl, etc.; R2 = (un)substituted Ph, CONHCHR5CO2R6 (R5 = alkyl, cycloalkyl, etc., R6 = H or protecting group); CONH-heterocyclyl, etc.; R3 = (un)substituted pyridyl or imidazolyl; R4 = H, alkyl, halo, aryl, etc.; X is absent or X1NR4X2, X1OX2 (X1 = absent, alkylene, or alkenylene; X2 = absent, CH2, CH2CH2, CHMe, etc.)] were prepd. Thus, [4-(3-pyridyloxymethylene)-2-phenoxybenzoyl]methionine (I) was prepd. by coupling of 4-(3-pyridyloxymethylene)-2-phenoxybenzoic acid (synthesis described) with methionine Me ester hydrochloride, followed by sapon. Compd. I showed 92% inhibition of protein farnesyl transferase at 1 .mu.M.

AN 1997:436061 CAPLUS

DN 127:51002

TI Inhibitors of protein isoprenyl transferases

IN Sebti, Said M.; Hamilton, Andrew D.; Rosenberg, Saul H.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce; Tasker, Andrew S.; Wasicak, James T.; Winn, Martin

PA University of Pittsburgh, USA

SO PCT Int. Appl., 260 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9717070	A1	19970515	WO 1996-US17092	19961105
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9675975	A1	19970529	AU 1996-75975	19961105
	ZA 9609273	A	19980505	ZA 1996-9273	19961105
	EP 873123	A1	19981028	EP 1996-938647	19961105
	EP 873123	B1	20030409		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000500745	T2	20000125	JP 1997-518208	19961105
	AT 236632	E	20030415	AT 1996-938647	19961105
PRAI	US 1995-7247P	P	19951106		
	WO 1996-US17092	W	19961105		

OS MARPAT 127:51002

IT **191102-65-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitors of protein isoprenyl transferases)

RN 191102-65-5 CAPLUS

CN L-Methionine, N-[[5-[[(1-oxido-3-pyridinyl)carbonyl]amino][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2003 ACS

AB Nucleophilic substitution of the nitro group in 4-nitro-3-pyridinecarboxanilide 1-oxide afforded 4-hydroxy-, 4-chloro-, 4-methoxy-, 4-ethoxy-, and 4-dimethylamino-3-pyridinecarboxanilide oxides. The 1H and 13C NMR chem. shifts of the pyridine moiety were correlated with the Hammett consts. of the substituent in position 4, with the exception of the 4-hydroxy deriv. The reason of this phenomenon is discussed.

AN 1995:885819 CAPLUS

DN 124:55761

TI Nucleophilic substitution in a series of 4-nitronicotinic acid 1-oxide derivatives

AU Pohl, Radek; Prutianov, Viktor; Smrckova-Voltrova, Svatava

CS Dep. Org. Chem., Prague Inst. Chem. Technol., Prague, 166 28, Czech Rep.

SO Collection of Czechoslovak Chemical Communications (1995), 60(7), 1170-7
CODEN: CCCCAK; ISSN: 0010-0765

PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic

DT Journal

LA English

OS CASREACT 124:55761

IT **172225-04-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(nucleophilic substitution of nitronicotinic acid 1-oxide derivs.)

RN 172225-04-6 CAPLUS

CN 3-Pyridinecarboxamide, 4-nitro-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)